Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.
This article reviews the therapeutic approaches in children with Vogt-Koyanagi-Harada (VKH) syndrome, and reports on a 9-year-old girl with progressive visual loss due to VKH syndrome in spite of treatment. In previous reports, corticosteroids were found to be the most effective agents in the treatment of VKH syndrome, while combination therapies with cyclosporine, methotrexate, or azathioprine were used with favorable results in refractory cases. In the current case, none of the treatments sufficiently stabilized the vision, but triple combination of corticosteroids, cyclosporine, and methotrexate suppressed the relapses of intraocular inflammation. Treatment of children with VKH syndrome is challenging. Various treatment modalities have been reported with various responses, but there is still no definite treatment regimen, and the treatment is usually individualized in pediatric VKH cases.
Berker
Nilufer
N
Department of Retinal and Uveal Diseases, Ulucanlar Eye Research Hospital, Ankara, Turkey. niluferberker@hotmail.com
Ozdamar
Yasemin
Y
Soykan
Emel
E
Ozdal
Pinar
P
Ozkan
Seyhan Sonar
SS
D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012008:Recurrence; D042262:Retinoscopy; D014607:Uveomeningoencephalitic Syndrome / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D015354:Vision, Low / Q000209:etiology* / Q000503:physiopathology; D014792:Visual Acuity
D005938:Glucocorticoids; D007166:Immunosuppressive Agents